# Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel

> **NCT06538272** · PHASE2 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 210 (actual)

## Conditions studied

- CIPN - Chemotherapy-Induced Peripheral Neuropathy

## Interventions

- **DRUG:** ONO-2910
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06538272
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-31
- **Primary completion:** 2024-09-19
- **Final completion:** 2024-09-19
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538272, "Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06538272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*